ANTI-PD-1/CTLA-4 Bi-specific Antibody (AK104) of Akeso Granted...
- Written by LATEST ASIANET NEWS RELEASES
- Published in Asia Net
LOS ANGELES, Aug. 13, 2020 /PRNewswire-AsiaNet/ -- Akeso, Inc (9926.HK) - a biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of new innovative antibody drugs that are affordable to patients worldwide - today announced that the U.S. Food and Drug...
Authors: LATEST ASIANET NEWS RELEASES
